Zhang W, Cui L, Zhang Y, He Y, Li X, Wang Y
Mol Neurobiol. 2025; .
PMID: 40087219
DOI: 10.1007/s12035-025-04840-6.
Chen B, Zhou H, Sun M, Yang W, Li Q, Yang K
J Neuroinflammation. 2025; 22(1):69.
PMID: 40055743
PMC: 11887262.
DOI: 10.1186/s12974-025-03380-z.
Kim J, Jang S, Choi J, Han K, Jung J, Oh S
Sci Rep. 2025; 15(1):7764.
PMID: 40044803
PMC: 11882889.
DOI: 10.1038/s41598-025-92370-5.
Mulate S, Molla B, Abera B, Hailemariam T, Zewde Y
Clin Case Rep. 2025; 13(2):e70180.
PMID: 39926640
PMC: 11805675.
DOI: 10.1002/ccr3.70180.
Cacciaguerra L, Storelli L, Pagani E, Preziosa P, Mesaros S, Martinelli V
Mult Scler. 2025; 31(2):140-158.
PMID: 39891565
PMC: 11789429.
DOI: 10.1177/13524585241307154.
Brain tissue integrity in neuromyelitis optica spectrum disorder through T1-w/T2-w ratio, MTR and DTI.
Boaventura M, Fragoso D, Avolio I, Pereira S, Callegaro D, Sato D
J Neurol. 2025; 272(2):157.
PMID: 39821642
DOI: 10.1007/s00415-024-12869-1.
Cerebellar Involvement in Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder.
Dinoto A, Cacciaguerra L, Krecke K, Chen J, Wingerchuk D, Weinshenker B
Neurol Neuroimmunol Neuroinflamm. 2024; 12(1):e200344.
PMID: 39661938
PMC: 11637506.
DOI: 10.1212/NXI.0000000000200344.
The Involvement of Glial Cells in Blood-Brain Barrier Damage in Neuroimmune Diseases.
Nagata S, Yamasaki R
Int J Mol Sci. 2024; 25(22).
PMID: 39596390
PMC: 11594741.
DOI: 10.3390/ijms252212323.
Effects of early intervention in neuromyelitis optica spectrum disorder patients with seropositive AQP4 antibodies.
Xue B, Li J, Xie D, Weng Y, Zhang X, Li X
Front Immunol. 2024; 15:1458556.
PMID: 39555058
PMC: 11563946.
DOI: 10.3389/fimmu.2024.1458556.
Cardioneuroablation eliminating cardiac asystole associated with area postrema syndrome: a case report and literature review.
Wang E, Li Y, Yu G, Liu G, Deng J, Wang Y
Front Cardiovasc Med. 2024; 11:1453166.
PMID: 39544310
PMC: 11560896.
DOI: 10.3389/fcvm.2024.1453166.
Integrated omics profiling reveals systemic dysregulation and potential biomarkers in the blood of patients with neuromyelitis optica spectrum disorders.
Xie Z, Zhou Q, Hu J, He L, Meng H, Liu X
J Transl Med. 2024; 22(1):989.
PMID: 39487546
PMC: 11529322.
DOI: 10.1186/s12967-024-05801-8.
"Lupus Myelitis" Revisited: A Retrospective Single-Center Study of Myelitis Associated With Rheumatologic Disease.
Krett J, Filippatou A, Barreras P, Pardo C, Gelber A, Sotirchos E
Neurol Neuroimmunol Neuroinflamm. 2024; 12(1):e200329.
PMID: 39442039
PMC: 11727606.
DOI: 10.1212/NXI.0000000000200329.
Optic Neuritis - The Evolving Spectrum.
Al-Ani A, Costello F
Ann Indian Acad Neurol. 2024; 27(5):471-481.
PMID: 39428946
PMC: 11575883.
DOI: 10.4103/aian.aian_602_24.
Antibodies in neurological diseases: Established, emerging, explorative.
Li L, Keles A, Homeyer M, Pruss H
Immunol Rev. 2024; 328(1):283-299.
PMID: 39351782
PMC: 11659937.
DOI: 10.1111/imr.13405.
NMOSD and MOGAD: an evolving disease spectrum.
Uzawa A, Oertel F, Mori M, Paul F, Kuwabara S
Nat Rev Neurol. 2024; 20(10):602-619.
PMID: 39271964
DOI: 10.1038/s41582-024-01014-1.
Targeting cytokine networks in neuroinflammatory diseases.
Becher B, Derfuss T, Liblau R
Nat Rev Drug Discov. 2024; 23(11):862-879.
PMID: 39261632
DOI: 10.1038/s41573-024-01026-y.
Is there a prodrome to NMOSD? An investigation of neurologic symptoms preceding the first NMOSD attack.
Lee S, Marrie R, Fadda G, Freedman M, Lee L, Muccilli A
Mult Scler. 2024; 30(11-12):1423-1435.
PMID: 39258406
PMC: 11529114.
DOI: 10.1177/13524585241275491.
Radiological features in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease-diagnostic criteria and lesion dynamics.
Pratt L, Meirson H, Rootman M, Ben-Sira L, Shiran S
Pediatr Radiol. 2024; .
PMID: 39243314
DOI: 10.1007/s00247-024-06023-2.
Brief research report: WGCNA-driven identification of histone modification genes as potential biomarkers in AQP4-Associated optic neuritis.
Cao Y, Yao W, Chen F
Front Genet. 2024; 15:1423584.
PMID: 39238786
PMC: 11374599.
DOI: 10.3389/fgene.2024.1423584.
Humanized-Aquaporin-4-Expressing Rat Created by Gene-Editing Technology and Its Use to Clarify the Pathology of Neuromyelitis Optica Spectrum Disorder.
Namatame C, Abe Y, Miyasaka Y, Takai Y, Matsumoto Y, Takahashi T
Int J Mol Sci. 2024; 25(15).
PMID: 39125739
PMC: 11311328.
DOI: 10.3390/ijms25158169.